The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther 1999; 82:241–50. .
The EGFR family and its ligands in human cancer signaling mechanisms and therapeutic opportunities. Eur J Cancer 2001; 37:S3–S8. .
The EGF receptor family as targets for cancer therapy. Oncogene 2000; 19:6550–65. , .
Untangling the ErbB signaling network. Nat Rev Mol Cell Biol 2001; 2:127–37. , .
et al. Nuclear localization of EGF receptor and its potential new role as a transcription factor. Nat Cell Biol 2001; 3:802–8. , ,
Localizing the EGF receptor. Nat Cell Biol 2002; 4:E22, author reply E22-3.5., , , .
EGF receptors as transcription factors: ridiculous or sublime? Nat Cell Biol 2001; 3:E209-11. , .
EGFR antagonist in cancer treatment. N Engl J Med 2008; 358:1160–74. , .
Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment. Endocr Relat Cancer 2003; 10:1–21. , , , , .
Rational combination of targeted therapies as a strategy to overcome the mechanisms of resistance to inhibitors of EGFR signaling. Curr Pharm Des. 2007; 13:3358–67. , , , , , .
When kinases meet mathematics: the systems biology of MAPK signalling. FEBS Lett 2005; 579:1891–5. , , .
Response to epidermal growth factor receptor inhibitors in nonsmall cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways. Clin Cancer Res 2003; 9:2316–26. , , , .
Transforming growth factor-alpha-induced transcriptional activation of the vascular permeability factor (VPF/VEGF) gene requires AP-2- dependent DNA binding and transactivation. EMBO J 1997; 16:750–9. , , .
Epidermal growth factor receptor biology (IMC-C225). Curr Opin Oncol 2001; 13:506–13. , , .
et al. The IgG1 monoclonal antibody cetuximab induces degradation of the epidermal growth factor receptor. J Clin Oncol 2004; 22 (abstract 234)., ,
A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc Natl Acad Sci USA 2001; 98:11598–603. , .
4E-BP1, a repressor of mRNA translation, is phosphorylated and inactivated by the Akt (PKB) signaling pathway. Genes Dev 1998; 12:502–13. , , , , .
et al. Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin Cancer Res 1999; 5:257–65. , ,
et al. A multi-centered phase I/II study of cetuximab in combination with paclitaxel and carboplatin in untreated patients with stage IV non-small cell lung cancer. J Clin Oncol 2005; 23:8786–93. , ,
Phase Ib/Ia study of anti-epidermal growth factor receptor antibody, cetuximab, in combination with gemcitabine/carboplatin in patients with advanced stage IV non-small cell lung cancer. Proc Am Soc Clin Oncol 2003; 22:643 (abstract 2587)., , , , , .
Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004; 22:1201–8. , , , , , .
et al. A phase I study of cetuximab in combination with cisplatin or carboplatin and 5-FU in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. Proc Am Assoc Cancer Res 2003; 22:2020. , ,
et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan refractory metastatic colorectal cancer. N Engl J Med 2004; 351:337–45. , ,
et al. Cetuximab plus irinotecan in heavily preatreated metastatic colorectal cancer progression on irinotecan. MABEL study. J Clin Oncol 2008; 26:5335–43. , ,
EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26:2311–9. , , .
et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007; 357:2040–8. , ,
et al. Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2007; 25:5225–32. , ,
et al. FOLFOX-4 cetuximab plus 5-FU/FA/oxaliplatin (FOLFOX-4) versus in the first-line treatment of metastatic colorectal cancer (mCRC): OPUS, a randomized phase II study. J Clin Oncol 2007; 25 (abstract 4035)., ,
et al. Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma. Ann Oncol 2006; 17:450–56. , ,
et al. Optimal dose of cetuximab (C) given every 2 weeks (q2w): a phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of weekly (q1w) and q2w schedules in patients (pts) with metastatic colorectal cancer (mCRC). J Clin Oncol 2006; 24:1425 (abstract 3085)., ,
et al. Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): the CRYSTAL trial. J Clin Oncol 2007; 25 (abstract 4000)., ,
et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy – refractory metastatic colorectal cancer. J Clin Oncol 2007; 25:1658–64. , ,
et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006; 354:567–78. , ,
et al. Cetuximab extends survival of patients or recurrent or metastatic SCCHN when added to first line platinum-based therapy results of a randomized phase III (EXTREME) study. Late-breaking abstract presented at the 43rd American Society of Clinical Oncology Annual Meeting, Chicago, 1–5 June 2007. , ,
et al. Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice. Nat Genet 1997; 15:146–56. , ,
Dermatological toxicities of panitumumab in the treatment of patients with metastatic colorectal cancer from two clinical studies. Annual Meeting Proceedings. Gastrointest Cancers Symp 2007; abstract 449. , , , .
et al. Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. J Clin Oncol 2004; 22:3003–15. , ,
et al. Update results from a dose and schedule study of panitumumab (ABX-EGF) monotherapy, in patients with advanced solid malignancies. J Clin Oncol 2005; 23:16S (abstract 3059)., ,
et al. Panitumumab antitumor activity in patients (pts) with metastatic colorectal cancer (mCRC) expressing > 10% epidermal growth factor receptor (EGFR). ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2006; 24(suppl. 18S): 3548. , , .
et al. Panitumumab with irinotecan/leucovorin/5-fluorouracil for first-line treatment of metastatic colorectal cancer. Clin Colorectal Cancer 2007; 6:427–32. , ,
et al. Panitumumab antitumor activity in patients (pts) with metastatic colorectal cancer (mCRC) expressing low (1–9%) or negative (1%) levels of epidermal growth factor receptor (EGFR). ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2006; 24(suppl. 18S): 3547. , ,
et al. Safety and efficacy of panitumumab monotherapy in patients with metastatic colorectal cancer (mCRC). J Clin Oncol 2005; 23:251s (abstract 3520)., ,
et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007; 25:1658–64. , ,
et al. Wild-type K-ras is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26:1626–31. , ,
et al. A randomized phase III of chemotherapy, bevacizumab, and panitumumab a compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol 2009; 27:672–80. , ,
et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 2005; 23:1803–10. , ,
et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to anti-EGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 2005; 6:279–86. , ,
RAS oncogenes: the first 30 years. Nat Rev Cancer 2003; 3:459–65. , .
et al. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res 2007; 67:2643–8. , ,
et al. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by cetuximab plus chemotherapy. Br J Cancer 2007; 96:1166–9. , ,
et al. K-ras and p16 aberrations confer poor prognosis in human colorectal cancer. J Clin Oncol 2001; 19:299–304. , ,
et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006; 66:3992–5. , ,
et al. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol 2008; 19:508–15 [epub ahead of print on 12 November 2007. , ,
et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008; 359:1757–65. , ,
et al. Kras status and efficacy in the first-line treatment of patients with metastic colorectal cancer (mCRC) treated with FOLFIRI with or without. The CRYSTAL experience. J Clin Oncol 2008; 26:5s (suppl; abstract 2)., ,
et al. Kras status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: the OPUS experience. J Clin Oncol 2008; 26:178s (suppl; abstract 4000)., ,
et al. Correlation of KRAS status (wild type [wt]versus mutant [mt]) with efficacy to first-line cetuximab in a study of cetuximab single agent followed by cetuximab + FOLFIRI in patients (pts) with metastatic colorectal cancer (mCRC). J Clin Oncol 2008; 26:2105 (suppl; abstract 4129)., ,
et al. Wild-type BRAF is required to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 2008; 26:5705–12. , ,
Antibody-based therapy for solid tumors. Cancer J 2008; 14:178–83. , , .
From XenoMouse technology to panitumumab, the first fully human antibody product from transgenic mice. Nat Biotechnol. 2007; 25:1134–43. , , , , .
The humoral immune response. In: Janeway's immunobiology, 7th edn. New York: Garland Science, 2008. , , .
et al. The activation of natural killer cell effector functions by cetuximab-coated, epidermal growth factor receptor positive tumor cells is enhanced by cytokines. Clin Cancer Res 2007; 13:6419–28. , ,
CTLs rapidly capture membrane fragments from target cells in a TCR signaling-dependent manner. J Immunol 2001; 166:3645–9. , , , , .
What is trogocytosis and what is its purpose? Nat Immunol 2003; 4:815. , .
Capture of target cell membrane components via trogocytosis is triggered by a selected set of surface molecules on T or B cells. J Immunol 2007; 178:3637–47. , , , , .
Within peripheral blood mononuclear cells, antibody-dependent cellular cytotoxicity of rituximab-opsonized Daudi cells is promoted by NK cells and inhibited by monocytes due to shaving. J Immunol 2008; 181:2916–24. , , .
High shed antigen levels within tumors: an additional barrier to immunoconjugate therapy. Clin Cancer Res 2008; 14:7981–6. , .
Binding of rituximab, trastuzumab, cetuximab, or mAb T101 to cancer cells promotes trogocytosis mediated by THP-1 cells and monocytes. J Immunol 2008; 181:8120–32. , , , , .
Signal integration: a framework for understanding the efficacy of therapeutics targeting the human EGFR family. J Clin Invest 2008; 118:3574–81. , , .
Monoclonal antibodies in the treatment of advanced colorectal cancer. Eur J Surg Oncol 2007; 33 (Suppl. 2): S24–34. Epub 2007 5 November. Review. PubMed PMID: 17981431. , , , , , .
The impact of cetuximab on the capecitabine plus oxaliplatin (XELOX) combination in first-line treatment of metastatic colorectal cancer (MCC): a randomized phase II trial of the Swiss Group for Clinical Cancer Research (SAKK). J Clin Oncol 2006; 24:585 (abstract 3551)., , .